Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients

American Journal of Nephrology

Volumn 21, Issue 5, 2001, Pages 373-377

  Małyszko, Jolanta ^a   Małyszko, Jacek S ^a   Hryszko, Tomasz ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Hemostasis; Lipids; Platelet aggregation; Thrombomodulin

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTILIPEMIC AGENT; ARACHIDONIC ACID; CHOLESTEROL; COLLAGEN; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PROTHROMBIN; RISTOCETIN; SIMVASTATIN; STATIN; THROMBOMODULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ANTILIPEMIC AGENTS; ARACHIDONIC ACID; CHOLESTEROL; COLLAGEN; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PLATELET AGGREGATION; RISTOCETIN; SIMVASTATIN; STATISTICS, NONPARAMETRIC; THROMBOMODULIN;

EID: 0035742044     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046277     Document Type: Article

References (27)

1. Is atherosclerosis accelerated by CAPD?
2. Cardiovascular risk factors in chronic renal failure and hemodialysis populations
3. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome
4. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis
5. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients
6. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients
7. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
8. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents
9. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor
10. Haemostatic parameters related to lipids and adhesion molecules
11. Factor VII hyperactivity in chronic dialysis patients
12. Fibrinolytic activity, clotting factors and long-term incidence of ischemic heart disease in Northwick Park Heart Study
13. Platelet function, hemostasis and serotonin in acute and chronic renal failure
14. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis
15. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes
16. Cyclosporine and FK 506 affect platelet function in vitro
17. Aggregation of blood platelets by adenosine diphosphate and its reversal
18. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis
19. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis
20. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
21. The action of lovastatin on platelet function and platelet eicosanoid receptor in type II hypercholesterolemia
22. Plasma thrombomodulin in renal disease: Effects of renal function and proteinuria
23. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients
24. Von Willebrand factor and soluble E-selectin in hyperlipidemia: Relationship to lipids and vascular disease
25. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxy-peptidase B
26. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis
27. Recent advances in statins and the kidney